A number of biotech stocks were soaring in Friday’s premarket following positive news.
Biogen Idec Inc (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037) which showed statistical significance with 3mg, 10mg doses for Alzheimer’s treatment.
Biogen Idec traded at $464.71 in the premarket, up 7.16 percent
Gilead Sciences traded at $102.40, up 0.95 percent.
Prothena Corporation PLC (NASDAQ: PRTA) reported that its PRX002 protein Immunotherapy for Parkinson’s Disease met primary objective of Phase 1 study, found to be safe, well tolerated.
Prothena soared to $41.87 in the premarket, up 43.24 percent.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported that data showed OCA-treated patients with nonalcoholic steatohepatitis (NASH) saw improvements in its Phase 2b FLINT trial.
Intercept Pharmaceuticals surged 8 percent to $311.71.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.